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Background: This study is to evaluate the associations between long-term survival and stage I breast
cancer by examining the hormonal receptor (HR) and human epidermal growth factor receptor-2 (HER2)
status.
Materials and methods: A total of 1595 breast cancer patients who were seen from 1990 to 2008 with
surgery as ﬁrst treatment and pathology stage I (T1N0) were included in this study. HR and HER2 status
were used to approximate breast cancer subtypes. Additionally, ten-year relapse-free survival (RFS) rate
and failure patterns of each subtype were evaluated. Multivariate analyses were performed in each
subtype to identify the risk factors of recurrence.
Results: Luminal-like (HR positive and HER2 negative) stage I patients showed a 10-year RFS rate of
89.5%, HER2 positive 92.9%, triple negative 91.1%, and unclassiﬁed subtype 86.2% (p ¼ 0.089), respec-
tively. The 10-year overall survival was 94.1% in luminal-like subtype, 90.1% in HER2, 94.5% in triple
negative, and 85.3% in unclassiﬁed subtype. The independent recurrence risk factors in luminal-like
subtype were 40 years of age (hazard ratio [HR] 2.2, 95% conﬁdence interval [CI], 1.1e4.4), nuclear
grade III (HR 2.7, CI, 1.4e5.3), and tumor >1.5 cm (HR 1.8, CI 1.0e3.4), and in unclassiﬁed subtype 40
years of age, tumor >1.5 cm, and adjuvant hormonal therapy. No risk factors were identiﬁed in HER2 or
triple negative subtype.
Conclusions: The factors associated with poor prognosis of stage I breast cancer vary by subtype. No risk
factors were identiﬁed in HER2 subtype or triple negative patients. Tumor size >1.5 cm, age 40 years
and nuclear grade 3 are the risk factors associated with poor prognosis in luminal-like subtype.
Copyright © 2015, The Chinese Oncology Society. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The assessment of hormonal receptor (HR) and human
epidermal growth factor receptor-2 (HER2) status by immunohis-
tochemistry (IHC) groups breast cancer into three major subtypes:
1) luminal-like subtype (HR positive/HER2 negative); 2) HER2ncology, Koo Foundation Sun
Taipei City 112, Taiwan.
ncology Society.
Society. Production and hosting bysubtype (HER2 positive and HR negative/positive); and 3) triple
negative subtype (HR negative/HER2 negative).1
Luminal-like is the most common breast cancer subtype with
with a superior survival rate than HER2 and triple negative sub-
types1,2; however, little is known about the failure patterns or long-
term outcomes of each subtype. Unlike other breast cancer sub-
types, more than half of the recurrences in luminal-like subtype
occur 6 or more years after treatment.3 Therefore, long-term sur-
vivorship follow-up in large patient databases is required for the
development of better therapeutic decisions and follow-up pro-
grams.3 In this study, we examined the prognostic factors sur-
rounding the 10-year breast cancer recurrence-free survival (RFS)Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
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cancer subtype would have different clinical behavior and failure
patterns.
2. Material and methods
Patients with breast cancer treated between 1990 and 2008 in
our hospital who met the following criteria were included in this
study: 1) primary surgeries (modiﬁed radical mastectomy, simple
mastectomy with sentinel lymph node biopsy, or breast conserving
surgery with axillary lymph node dissection or sentinel lymph
node biopsy) as ﬁrst treatment, and 2) pathology stage I (T1N0).
Patients with the following conditions were excluded: 1) pre-
operative chemotherapy, 2) bilateral breast cancer at the time of
diagnosis (on account of difﬁcult calculations of recurrent events),
and 3) distant metastases at initial presentation.
All treatment decisions are made based on the Breast Cancer
Clinical Practice Guidelines developed in our hospital since 1993.4
These are revised annually in ways similar to those revisions for
the guidelines developed by the National Cancer Center Network
(NCCN). In principle, patients with HR positive status would have
adjuvant hormonal therapy, and patients with primary tumor
>1 cm and grade 2e3 would be given adjuvant chemotherapy.
Patients with breast-conserving surgery would have adjuvant
radiotherapy.
All clinical information of the patients was collated prospec-
tively into a comprehensive Breast Cancer database in our hospital
with consents, and approved by the Institutional Review Board
(IRB). Information collected in this database consisted of the
following: 1) a general data form, which documents patient de-
mographic information, general medical and family history as well
as speciﬁc, clinical, and treatment history; (2) a pathologic review
form, which records pathological information of tumor tissues; (3)
a chemotherapy form, which contains chemotherapy information
and related complications; (4) a radiotherapy form, which contains
radiotherapy information and related complications; (5) a follow-
up form, which is submitted every 6e12 months after the
completion of all treatments or when tumor relapse is observed;
and (6) a late complication form, which is submitted when any late
complication is observed.
SAS programs were written for data input, data management,
data quality control, analysis, and presentation. For data quality
control, our pathologists recorded pathological information on theFig. 1. Stage I breast cancepathology review form when the surgical specimen was available.
The clinicians audited the charts to ensure that the clinical infor-
mation entered into the Breast Cancer Data Base was accurate. All
data entries were done twice by two independent data processors.
On-line logic check was available when the data was ﬁrst entered.
We also regularly performed logic analysis between data forms and
within of each form.4
2.1. Statistical analysis
The clinical risk factors such as age at diagnosis, primary tumor
size, axillary lymph node status, nuclear grade, Scarff-Bloom-
Richardson (SBR) histological grade, lymphovascular invasion
(LVI), hormonal receptor status, extra-capsular-extension (ECE) of
axillary lymph node, multifocality, multicentricity, surgical type,
and adjuvant treatments were included elements of analysis. The
box proportional hazards regression models were used to assess
the prognostic signiﬁcance of the risk factors related to disease
recurrences.5 We used the step-down regression analysis of breast
cancer relapse-free survival (RFS) to evaluate all prognostic vari-
ables mentioned above. The duration of RFS was deﬁned as the
‘time from the ﬁrst day of treatment to the day when locoregional
recurrence or distant metastasis is observed.’ The Kaplan-Meier
method was used to show RFS curves,6 and the Log-rank test and
Chi-squared test were used to assess the statistical signiﬁcance of
the difference in the probabilities of RFS between the speciﬁc pa-
tient subsets.7
3. Results
Of the 5508 newly diagnosed breast cancer patients treated in
our hospital in the period of 1990 to 2008, 1595 (29.0%) patients
with T1N0 (stage I) diseasewere included in this studywith the last
follow-up date set at August 31, 2011. The median follow-up in-
terval was 67.8 months. Fig. 1 shows the distribution of breast
cancer subtypes in stage I patients. Luminal-like subtype amounted
to 51.4%, HER2 subtype 17.1%, triple negative 10.7%, and unclassiﬁed
20.8% of the patients. Table 1 shows patient characteristics by
subtypes. More than 40% of the luminal-like and HER2 patients
were between the ages of 41e50, while only 29.2% of the triple
negative subtype, which was the age of usual diagnosis at >50 years
(45.6%) (p¼ 0.0015). The most shared histology in this subtype was
inﬁltrating ductal carcinoma (97.4%, p < 0.0001). Triple negativer subtype distribution.
S.H.-C. Cheng et al. / Journal of Cancer Research and Practice 3 (2016) 1e8 3subtype was seen as more frequently associated with primary tu-
mor size >1 cm (74.9%). HER2 and triple negative subtypes were
more associated with high-grade tumors (nuclear grade and his-
tological grade 3 than the luminal-like subtype (p < 0.0001). HER2
patients were seen most commonly with multifocal or multicentricTable 1
Patient characteristics according to breast cancer subtypes in stage I patients (n ¼ 1595)
Patient characteristics Immunohistochemistry subtype
Luminal-like HER2
Age at diagnosis
35 76(9.3) 21(7.7)
36e40 129(15.7) 37(13.6)
41e50 344(41.9) 111(40.8)
51e60 154(18.8) 77(28.3)
>60 118(14.4) 26(9.6)
Menstruation status
Premenopausal 578(70.4) 185(68.0)
Postmenopausal 241(29.4) 86(31.6)
Unknown 2(0.2) 1(0.4)
Surgery
BCS 411(50.1) 83(30.5)
Mastectomy 410(49.9) 189(69.5)
Histology
Favorablea 60(7.3) 1(0.4)
Inﬁltrating ductal 667(81.2) 265(97.4)
Other invasive 94(11.5) 6(2.2)
Tumor size (cm)
1.0 283(34.5) 108(39.7)
>1.0 538(65.5) 164(60.3)
Hormonal receptor
ERþ/PRþ 693(84.4) 94(34.6)
ERþ/PR 102(12.4) 32(11.8)
ER/PRþ 26(3.2) 15(5.5)
ER/PR 0(0.0) 131(48.2)
HER2
Negative (0 or 1þ) 821(100) 0(0.0)
Indeterminate (þþ) 0(0.0) 0(0.0)
Positive (þþþ) 0(0.0) 272(100)
Nuclear grade
Grade 1 316(38.5) 12(4.4)
Grade 2 391(47.6) 65(23.9)
Grade 3 114(13.9) 191(70.2)
Unknown 0(0.0) 4(1.5)
SBR histological grade
Grade 1 254(30.9) 9(3.3)
Grade 2 263(32.0) 57(21.0)
Grade 3 83(10.1) 130(47.8)
Unknown 221(26.9) 76(27.9)
LVI
Absent 613(74.7) 208(76.5)
Focal 156(19.0) 42(15.4)
Prominent 35(4.3) 14(5.2)
Unknown 17(2.1) 8(2.9)
Multifocal or multicentric
Absent 654(79.7) 185(68.0)
Present 149(18.2) 77(28.3)
Unknown 18(2.2) 10(3.7)
Adjuvant R/T
Yes 408(49.7) 88(32.4)
No 413(50.3) 184(67.6)
Adjuvant H/T
Yes 768(93.5) 132(48.5)
No 53(6.5) 140(51.5)
Adjuvant C/T
Yes 379(46.2) 168(61.8)
No 442(53.8) 104(38.2)
Note: P value was calculated by Chi-squared test.
Abbreviation: ECE, extracapsular extension; LVI, lymphovascular invasion; LN, lymph n
chemotherapy.
a Favorable histology: medullary, tubular, or mucinous carcinoma.tumors, and consequently, patients with this subtype had fewer
breast conserving surgeries than other subtypes (30.5% versus
50.1e50.3%, p < 0.0001). Adjuvant chemotherapy was administered
to the HER2 and triple negative groups (61.8% and 73.1%) more than
the luminal-like group (46.2%, p < 0.0001)..
P value
Triple negative Unclassiﬁed
20(11.7) 37(11.2) 0.0015
23(13.5) 52(15.7)
50(29.2) 136(41.1)
53(31.0) 58(17.5)
25(14.6) 48(14.5)
103(60.2) 235(71.0) 0.2009
68(39.8) 95(28.7)
0(0.0) 1(0.3)
86(50.3) 110(33.2) <0.0001
85(49.7) 221(66.8)
6(3.5) 26(7.9) <0.0001
154(90.1) 271(81.9)
11(6.4) 34(10.3)
43(25.2) 124(37.5) 0.0121
128(74.8) 207(62.5)
0(0.0) 185(55.9) <0.0001
0(0.0) 30(9.1)
0(0.0) 12(3.6)
171(100) 53(16.0)
171(100) 9(2.7) <0.0001
0(0.0) 321(97.0)
0(0.0) 1(0.3)
7(4.1) 62(18.7) <0.0001
29(17.0) 116(35.1)
133(77.8) 125(37.8)
2(1.2) 28(8.5)
6(3.5) 47(14.2) <0.0001
20(11.7) 73(22.1)
106(62.0) 90(27.2)
39(22.8) 121(36.6)
131(76.6) 242(73.1) <0.0001
34(19.9) 37(11.2)
5(2.9) 19(5.7)
1(0.6) 33(10.0)
145(84.8) 252(76.1) <0.0001
25(14.6) 51(15.4)
1(0.6) 28(8.5)
86(50.3) 103(31.1) <0.0001
85(49.7) 228(68.9)
11(6.4) 230(69.5) <0.0001
160(93.6) 101(30.5)
125(73.1) 164(49.6) <0.0001
46(26.9) 167(50.5)
ode; Scarff-Bloom-Richardson, SBR; H/T, hormonal therapy; R/T, radiotherapy; C/T,
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The 5-year and 10-year RFS rates for luminal-like subtype were
95.6% and 89.5%, respectively, 92.9% and 92.9% for HER2, 93.0% and
91.1% for triple negative, and 91.2% and 86.2% for unclassiﬁed
subtype (Fig. 2). The 10-year overall survival was 94.1% in luminal-
like subtype, 90.1% in HER2, 94.5% in triple negative, and 85.3% in
unclassiﬁed subtype.3.2. Luminal-like subtype
Univariate analysis revealed that the risk factors associated with
recurrence in luminal-like subtype patients were age 40, nuclear
grade III, and tumor size >1.5 cm (Table 2). Multivariate analysis on
the Cox's proportional hazards model revealed that the indepen-
dent risk factors of recurrence were age 40 (hazard ratio 2.2, CI
1.1e4.4), nuclear grade III (hazard ratio 2.7, CI 1.4e5.3), and tumor
>1.5 cm (hazard ratio 1.8, CI 1.0e3.4). The 10-year RFS rates for
grade I-II (luminal A-like subtype) patients versus grade III (luminal
B-like subtype) were 90.9% and 81.7%, respectively (p < 0.0001,
Fig. 3).3.3. HER2 subtype
For the HER2 subtype (Table 2), no clinical or pathological fac-
tors were identiﬁed as poor prognostic factors on univariate or
multivariate analyses. The only borderline risk factor was for pa-
tients age 60 and older (hazard ratio 3.8, 95% CI 0.9e17, p value
0.08).3.4. Triple negative subtype
There was no risk factor identiﬁed in triple negative subtype on
univariate or multivariate analyses. Patients of age 40 showed a
hazard ratio of 7.1(CI 0.9e59), but the p value did not reach sta-
tistical signiﬁcance (p¼ 0.07). A primary tumor >1 cm had a higher
rate of recurrence (8.6%, 11/128) than a tumor 1 cm or less (2.3%, 1/
43), but the p value was 0.2. Low-grade tumor (nuclear grade IeII)
in this subtype showed excellent survival with a recurrence rate at
only 1/36 (2.8%). Adjuvant chemotherapy and radiotherapy are
associated with better survival but the p values also were
insigniﬁcant.Fig. 2. Relapse-free survival in each3.5. Unclassiﬁed subtype
The univariate analysis showed that risk factors of the unclas-
siﬁed subtype were nearly similar to those in the luminal-like
subtype; 84% of the patients in this subtype were HR positive and
97% HER2 indeterminate. The independent risk factors for unclas-
siﬁed subtype were age 40 (hazard ratio 3.6, CI 1.6e8.1), tumor
>1.5 cm (hazard ratio 2.5, CI 1.2e5.0), and adjuvant hormonal
therapy (hazard ratio 0.5, CI 0.2e0.9) (Table 2).
3.6. Patterns of failure
The highest relapse rate from the index breast cancer was
observed in luminal B-like (NG III) patients (19.9%), followed by
unclassiﬁed (9.1%), triple negative (7.0%) and HER2 patients (5.9%).
Luminal A-like (NG I-II) patients had the lowest rate of relapse at
only 4.1% (Table 3). Failure pattern analyses revealed that median
months of relapse are related to subtype (Fig. 4): the median
number of months of relapse in luminal A-like subtype was
58.6months, luminal B-like 35.3months, HER2 22.2, triple negative
18.8, and unclassiﬁed subtype 33.1months. The dominating pattern
of failure in luminal A-like subtype was locoregional recurrent (17/
29, 59%), and metastasis for the other subtypes (Table 4). Contra-
lateral breast cancer (CBC) and 2nd cancer were more common
among luminal A-like and HER2 subtypes (Fig. 5), which occurred
in nearly 50% of the patients.
4. Discussion
Three major subtypes with different clinical and pathological
characteristics share similar outcomes after 10-year follow-up; the
differences mainly lie in age at diagnosis, tumor grading, lympho-
vascular invasion, andmultiple foci of tumors (Table 1). The 10-year
RFS rates between luminal-like, HER2 and triple negative subtypes
range from 89.5% to 92.9% (Fig. 1). The observation of 10-year RFS
showing no difference among subtype could be explained by the
following factors: (1) patients with triple negative and HER2 sub-
types had more chemotherapy than those with luminal-like sub-
type (Table 1); (2) 37% of patients with HR positive had incomplete
adjuvant hormonal therapy, i.e. less than 4-year treatment
(Table 4). It has been conﬁrmed that a statistically signiﬁcant pro-
longation of RFS related to longer treatment durationwas observed
(HR, 0.74; 95% CI, 0.59 to 0.93) in ER-positive patients.8 The 10-year
RFS in luminal-like subtype could be improved if 10-year adjuvantsubtype of stage I breast cancer.
Table 2
Univariate and multivariate analyses of factors associated with breast cancer recurrences by subtype.
Variables N Relapse#(%) Univariate Multivariate
Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Luminal-like subtype
Age at diagnosis
40 205 21(10.2) 2.5(1.3e5.0.) 0.009 2.2(1.1e4.4) 0.03
41e50 344 13(3.8) 1.0 1.0
51e60 154 6(3.9) 1.1(0.4e2.8) 0.88 1.0(0.4e2.6) 0.96
>60 118 3(2.5) 0.8(0.2e2.7) 0.70 0.8(0.2e2.7) 0.69
Nuclear grade
IeII 707 29(4.1) 1.0 1.0
III 114 14(12.3) 3.4(1.8e6.5) 0.0002 2.7(1.4e5.3) 0.003
LVIþþþ
Yes 35 0(0.0) e
No 769 39(5.1) e
T size
1.5 cm 600 25(4.2) 1.0 1.0
>1.5 cm 221 18(8.1) 2.1(1.1e3.8) 0.02 1.8(1.0e3.4) 0.05
ER status
ER (þ) 795 41(5.2) 0.7(0.2e3.0) 0.66
ER () 26 2(7.7) 1.0
Surgery
MRM 410 21(5.1) 0.9(0.5e1.6) 0.65
BCS 411 22(5.4) 1.0
Adjuvant H/T
Yes 768 36(4.7) 1.0 0.01
No 53 7(13.2) 2.8(1.2e6.3)
Adjuvant C/T
Yes 379 26(6.9) 1.0 0.10
No 442 17(3.9) 0.6(0.3e1.1)
Adjuvant R/T
Yes 408 20(4.9) 1.0 0.83
No 413 23(5.6) 1.1(0.6e1.9)
HER2 subtype
Age at diagnosis
40 58 4(6.9) 2.0(0.5e8.2) 0.31
41e50 111 4(3.6) 1.0
51e60 77 5(6.5) 1.9(0.5e7.0) 0.35
>60 26 3(11.5) 3.8(0.9e17) 0.08
Nuclear grade
IeII 77 7(9.1) 1.0
III 191 9(4.7) 0.5(0.2e1.3) 0.17
LVIþþþ
Yes 14 1(7.1) 1.6(0.2e12) 0.65
No 250 13(5.2) 1.0
T size
1.0 cma 108 7(6.5) 1.0
>1.0 cm 164 9(5.5) 0.8(0.3e2.1) 0.21
ER status
ER (þ) 127 9(7.1) 1.4(0.5e3.7) 0.52
ER () 145 7(4.8) 1.0
Surgery
MRM 189 10(5.3) 0.8(0.3e2.1) 0.62
BCS 83 6(7.2) 1.0
Adjuvant H/T
Yes 132 9(6.8) 1.0 0.71
No 140 7(5.0) 0.8(0.3e2.2)
Adjuvant C/T
Yes 168 9(5.4) 1.0 0.43
No 104 7(6.7) 1.5(0.6e4.0)
Adjuvant R/T
Yes 88 6(6.8) 1.0 0.69
No 184 10(5.4) 0.8(0.3e2.2)
Triple negative subtype
Age at diagnosis
40 43 6(14.0) 7.1(0.9e59) 0.07
41e50 50 1(2.0) 1.0
51e60 53 4(7.6) 4.0(0.5e36) 0.21
>60 25 1(4.0) 1.8(0.1e28) 0.68
Nuclear grade
IeII 36 1(2.8) 1.0
III 133 11(8.3) 3.0(0.4e23) 0.29
LVIþþþ
Yes 5 0(0.0) e
No 165 12(7.3) e
(continued on next page)
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Table 2 (continued )
Variables N Relapse#(%) Univariate Multivariate
Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
T size
1.0 cma 43 1(2.3) 1.0
>1.0 cm 128 11(8.6) 3.8(0.5e29) 0.20
ER status
ER (þ) 0 0(0.0) e
ER () 171 12(7.0) e
Surgery
MRM 85 7(8.2) 1.4(0.4e4.4) 0.57
BCS 86 5(5.8) 1.0
Adjuvant H/T
Yes 11 2(18.2) 1.0 0.20
No 160 10(6.3) 0.4(0.08e1.7)
Adjuvant C/T
Yes 125 8(6.4) 1.0 0.56
No 46 4(8.7) 1.4(0.4e4.7)
Adjuvant R/T
Yes 86 4(4.7) 1.0 0.25
No 85 8(9.4) 2.0(0.6e6.7)
Unclassiﬁed subtype
Age at diagnosis
40 89 17(19.1) 3.4(1.5e7.7) 0.003 3.6(1.6e8.1) 0.002
41e50 136 9(6.6) 1.0 1.0
51e60 58 4(6.9) 1.1(0.3e3.6) 0.88 1.1(0.3e3.5) 0.91
> 60 48 3(6.3) 1.2(0.3e4.6) 0.76 1.6(0.4e6.0) 0.50
Nuclear grade
IeII 178 17(9.6) 1.0
III 125 13(10.4) 1.1(0.5e2.2) 0.81
LVIþþþ
Yes 19 3(15.8) 1.4(0.4e4.5) 0.62
No 279 28(10.0) 1.0
T size
 1.5 cm 229 17(7.4) 1.0 1.0
> 1.5 cm 102 16(15.7) 1.9(0.9e3.7) 0.08 2.5(1.2e5.0) 0.01
ER status
ER (þ) 216 16(7.4) 0.8(0.3e2.0) 0.64
ER () 65 6(9.2) 1.0
Surgery
MRM 221 19(8.6) 0.6(0.3e1.2) 0.16
BCS 110 14(12.7) 1.0
Adjuvant H/T
Yes 230 17(7.4) 1.0 0.02 1.0 0.03
No 101 16(15.8) 2.2(1.1e4.4) 2.2 (1.1e4.4)
Adjuvant C/T
Yes 164 20(12.2) 1.0 0.25
No 167 13(7.8) 0.7(0.3e1.3)
Adjuvant R/T
Yes 103 12(11.7) 1.0 0.42
No 228 21(9.2) 0.7(0.4e1.5)
a Among tumor size 1.0 cm, 65.7% (71/108) and 41.9% (18/43) patients with HER2-positive and triple negative subtypes had primary tumor 0.5 cm.
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ASCO Adjuvant Endocrine Therapy Guidelines 2014.9 However,
when the observation period is shortened to 5 years, the luminal-
like breast has the highest 5-year RFS among the three major
subtypes (95.6% vs. 92.9% and 93%, p ¼ 0.64). The RFS in luminal-
like subtype after 5 years shows a decline. There is no decline of
RFS after 5-year follow-up in the HER2 subtype (Fig. 1), for which
late recurrence is uncommon, indicating that the beneﬁt of
extended hormonal therapy for HER2-positive patients should be
re-evaluated.
Others have observed the marked differences in clinicopatho-
logical characteristics between breast cancer subtypes by IHC
study. However, they reported that triple negative and HER2 pa-
tients are at high risk of recurrences after adjusting for age, stage
and histological grade.10 Our data support this observation only at
the 5-year follow-up, but not at the 10-year follow-up. In our study,
the poorest survival is observed in luminal B-like subtype (Fig. 3).The factors associated with poor prognosis in each subtype are
different. In luminal-like patients the risk factors associated with
breast cancer recurrence are age 40, nuclear grade III, and tumor
size >1.5 cm. The hazard ratios for each factor are 2.2, 2.7, and 1.8,
respectively (Table 3). The hazard ratio for tumor size >1.5 cm is
more signiﬁcant than using tumor 1 cm as the cutoff value (data is
not shown here). There are no risk factors identiﬁed in HER2-
positive and triple negative patients. These observations indicate
that the prognoses in each subtype should be evaluated separately.
Xue et al in southern China have reported similar ﬁndings, indi-
cating that the prognostic signiﬁcance of clinicopathological factors
may differ among subtypes.11
The prognosis of stage I HER2 subtype is not related to tumor
grading or tumor size. Tumor size alone cannot determine the
prognosis in this subtype; our data have shown similar risk of
recurrence (6.5% versus 5.5%) for T1a-b and T1c patients. It is
arguable to give chemotherapy and target therapy solely based on
Fig. 3. Relapse-free survival in luminal A-like versus luminal B-like breast cancer.
Table 3
Failure patterns and patient number of ﬁrst event by breast cancer subtype.
Subtype Patient number Breast cancer relapse (%) LRR only DM only Both LRR and DM CBC or 2nd cancers
Luminal A-like (NG IeII) 707 29 (4.1) 15 (2.1) 12 (1.7) 2 (0.3) 26 (3.7)
Luminal B-like (NG III) 114 14 (19.9) 6 (5.3) 7 (6.1) 1 (0.9) 5 (4.4)
HER2 positive 272 16 (5.9) 5 (1.8) 10 (2.7) 1 (0.4) 13 (4.8)
Triple negative 171 12 (7.0) 4 (2.3) 5 (2.9) 3 (1.8) 5 (2.9)
Unclassiﬁed 331 30 (9.1) 8 (2.4) 18 (5.4) 4 (1.2) 15 (4.5)
Abbreviation: NG, nuclear grade; LRR, locoregional recurrence; DM, distant metastasis; and CBC, contralateral breast cancer.
S.H.-C. Cheng et al. / Journal of Cancer Research and Practice 3 (2016) 1e8 7the tumor size for patients of this stage as recommended by NCCN
guidelines (2014 version 3.0).
For the triple negative subtype, patients with tumor size&1 cm
or nuclear IeII patients had excellent outcomes (recurrent rate 1/43
and 1/36, respectively), however, the patient number is too small
for delivery of a conclusion. ln the literature, triple negative breast
cancer is regarded as an aggressive disease that affects the young
patient population.12,13 Our patients in this study are mainly over
50 years of age (Table 1). Ethnic differences may exist between
Asian and Caucasian patients.14,15 The patient number in this study
is not high enough to detect risk factors of recurrence. Tumor
inﬁltrating lymphocytes are prognostic in triple negative subtypeFig. 4. Median months to ﬁrst relapse in each subtype.according to a recent study.16 Further study and investigation may
use this new factor to identify high-risk patients.
The factors associated with poor prognosis in unclassiﬁed sub-
type were age 40, tumor size >1.5 cm, and no adjuvant hormonal
therapy (Table 3). These observations are understandable because
this group of patients was mainly HR positive (84%) and HER2
indeterminate (Table 1). The unclassiﬁed subtype has the poorest
10-year RFS (86.2%) among the three major subtypes. This subtype
is similar to luminal B-like subtype, of which the 10-year RFS was
only 81.7% (Fig. 2). Luminal B breast cancer has lower expression of
hormone receptors, higher expression of proliferation markers, and
higher tumor grade than luminal A. It also exhibits worse prognosis
and has a distinct proﬁle of response to hormone therapy and
chemotherapy.9
Extended hormonal therapy has become the standard of care for
HR positive breast cancer patients.17,18 We have observed sub-
stantial late recurrences in luminal-like subtype, but none in theTable 4
Duration of adjuvant hormonal therapy in hormonal receptor (ER or PR) positive
patients (821/1001 are luminal-like).
Duration of adjuvant hormonal therapy Patient# % Total#
1 year 96 9.6 96
1e2 years 71 7.1 167
2e3 years 101 10.1 268
3e4 years 100 10 368
4e5 years 579 57.8 947
>5 years 54 5.4 1001
Fig. 5. Patterns of ﬁrst relapse in each subtype.
S.H.-C. Cheng et al. / Journal of Cancer Research and Practice 3 (2016) 1e88HER2 subtype (52% HR positive) (Fig. 2). Factors examined to date
are related to early recurrence, while those related to late recur-
rence remain unclear. Progesterone receptor positivity and lymph
node metastases signiﬁcantly correlated with late recurrence.19
Using molecular markers, Breast Cancer Index, which consisted of
two independent biomarkers, HOXB13:IL17BR (H:I) and the 5-gene
molecular grade index, was the only signiﬁcant prognostic test for
risk of late distant recurrence.20 Our study observed no late
recurrence after the initial treatment in 141 HER2 (þ)/HR (þ) pa-
tients (Table 1). Extended hormonal therapy for this subtype is
worthy of further investigation.
The major limitation of our observations are that they take place
in a hospital-based patient population of the Asian ethnicity, where
premenopausal women are predominant.4 Whether there is a
presence of racial difference is unknown. Validation by other in-
stitutions, especially in western countries, is necessary.
In summary, luminal-like, HER2 and triple negative breast
cancers have different clinicopathological manifestations and
prognostic factors. Although luminal A-like stage I breast cancer
has shown to achieve the best 5-year RFS, the 10-year RFS is similar
to that of the HER2 and triple negative subtypes. Luminal B-like
subtype has the worst 10-year RFS among all subtypes. Therefore,
future study exploring the disease entity of this subtype is
warranted.Conﬂict of interest
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